Cytune Pharma SAS
PPF Group owns a French biotechnology company Cytune Pharma SAS focused on researching and developing new therapies for immune modulation aimed at enhancing immune response of patients suffering from cancer and infectious diseases.
Accord Research is an independent Clinical Research Organization (CRO) fully incorporated into the PPF Group. The company is primarily dedicated to provide clinical research services for PPF’s biotechnology company SOTIO but also to third parties. The company is operating in Europe and USA with its own employees or on the basis of a long term subcontracted cooperation.
Autolus Therapeutics plc (“Autolus”) is a leader in bio T cell programming technologies and is developing a pipeline of next generation T cell therapies targeting both hematological cancers and solid tumors. Focused on the development of precisely targeted, controlled and highly active CAR-T cell products, Autolus aims to provide T cell therapies with very favorable safety profile and enhanced clinical efficacy to better recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.